Oncology Ventures

RISA Labs utilizes Multi-Agent Systems to reimagine healthcare, enhancing efficiency and elevating patient care. The company's MAS interface sparks innovation in healthcare, aiming to make healthcare administration more intelligent, responsive, and centered around patients.

Daymark Health is a healthcare company specializing in supportive care services for cancer patients. It connects primary care physicians, oncologists, and care teams to provide virtual and home-based care, symptom management, care navigation, social support, and mental health services. These services are delivered by nurse practitioners, social workers, and health partners, ensuring comprehensive, personalized care that addresses both medical and non-medical needs throughout the patient's treatment journey.

mPath Health develops a cloud-based digital platform that automates patient enrollment for life-saving screenings, focusing on cancers and other health conditions. This platform has been proven in medical literature to significantly enhance screening rates, improving patient care efficiently.

OncoveryCare operates a specialized virtual clinic dedicated to supporting survivors of critical illnesses, initially focusing on cancer patients post-treatment. Their mission is to provide comprehensive, whole-person care and foster community among survivors, aiming to reduce disparities in survivorship outcomes. Through their tailored platform, they enable patients to navigate survivorship more easily, offering tools and support to enhance their quality of life.

Reimagine Care is a health‑care company that delivers technology‑enabled services to support community‑based oncology practices and health‑system oncology departments. The company supplies the personnel, processes, and a robust technology platform that enable scalable, patient‑centric, and lower‑cost cancer care across multiple sites, including home‑based treatment. Founded in 2020 and headquartered in Nashville, Tennessee, Reimagine Care partners with health‑care systems and independent oncology practices to promote value‑based care and improve access to high‑quality cancer treatment.

Concr is a mission-driven techbio company that uses established methods from astrophysics to predict patient outcomes and treatment response to cancer therapies. The approach enables iterative learning from fragmented data across the drug development and clinical journey, producing accurate multi-modal tumor models without relying on large, homogeneous datasets. Its cloud-native platform FarrSight supports computational simulation of clinical trials, prediction of therapeutic response and biomarkers, and standard bioinformatics analyses. Headquartered in London with a wholly owned subsidiary in Brisbane, Concr provides a cloud-based system that identifies optimal treatments for individuals, reduces resistance, and offers patient-specific progression insights and evidence-based treatment plans to guide proactive therapy.